Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma
Epistemonikos ID: 882f7349a62e5d484f0e1596639786bb22135021
First added on: May 08, 2024